EUVIMEDEUVIMED entdecken
Crossref

Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target

Vaibhav K Tamrakar iD, Kuldeep Sharma, Pushpendra Singh, Anudita Bhargava, Sanjay Singh Negi

Cancer · 2026

DOI: 10.1002/cncr.70292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Vaibhav K Tamrakar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Papillomavirus Vaccines, Disease Eradication. Die Arbeit nennt 17 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer remains one of the most significant yet preventable causes of cancer‐related mortality among women in India. Current estimates indicate that the country reports approximately 127,000 new cases and nearly 80,000 deaths annually, accounting for about one fifth of the global burden. Despite advances in vaccination, screening, and molecular diagnostics, coverage remains critically low: fewer than 2% of women undergo screening, and less than 1% have received a human papillomavirus (HPV) vaccine. The introduction of the indigenous quadrivalent vaccine Cervavac in 2023 has provided renewed momentum; however, limitations in infrastructure, public awareness, and stratic barrier to implementation continue to hinder progress toward achieving the World Health Organization's 2030 elimination targets. This opinion article highlights the epidemiological landscape, diagnostic and programmatic barriers, and emphasis to repurpose India's vast coronavirus disease‐era reverse transcriptase‐polymerase chain reaction network for HPV molecular testing. Integrating HPV vaccination into the Universal Immunization Program and incorporating the HPV Nucleic Acid Amplification Test (NAAT) into the National Essential Diagnostics List (NEDL) are critical steps for accelerating India's pathway to cervical cancer elimination by 2030.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsPapillomavirus VaccinesDisease EradicationFemaleHumansIndiaHuman Papillomavirus VirusesVaccinationHealth PolicyEarly Detection of Cancer

Stichwörter der Autor:innen

CervavacNational Essential Diagnostics List (NEDL)Universal Immunization Programcervical cancer eliminationhuman papillomavirus (HPV)human papillomavirus (HPV) vaccinationhuman papillomavirus‐nucleic acid antigen test (HPV‐NAAT)reverse transcriptase‐polymerase chain reaction (RT‐PCR) repurposing

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Department of Microbiology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
  • Department of Microbiology, State-Level Virus Research and Diagnostic Laboratory, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.

ORCID-Profile: Vaibhav K Tamrakar

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Tamrakar, V. K., Sharma, K., Singh, P., Bhargava, A., & Negi, S. S. (2026). Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target. Cancer. https://doi.org/10.1002/cncr.70292

Vancouver

Tamrakar VK, Sharma K, Singh P, Bhargava A, Negi SS. Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target. Cancer. 2026. doi:10.1002/cncr.70292

BibTeX
@article{Tamrakar2026,
  author = {Tamrakar, Vaibhav K and Sharma, Kuldeep and Singh, Pushpendra and Bhargava, Anudita and Negi, Sanjay Singh},
  title = {Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70292}
}
Kostenlos starten →